Published in Cancer Weekly, January 11th, 2005
The net loss for the period was $2.3 million, or 7 cents per share, compared to a net loss of $1.0 million, or 6 cents per share, in the year-ago period. The larger net loss is due to increased spending for research and development, general administrative expenses including depreciation of recently purchased equipment to enhance formulation efforts, and consulting fees. Cash, cash equivalents and investment securities at October 31, 2004 stood at $9.8 million compared to $9.7 million at July 31, 2004.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.